RxDoctor Payments DataLook up a doctor →

Lynn Larsen

Nurse Practitioner · Ogden, UTNPI 1295058501

Payments from drug & device makers

$15,798in general payments, 2019–2025

Across 732 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Merck$921
  • Novartis$912
  • Johnson & Johnson$905
  • Astellas Pharma US Inc$839
  • Seagen Inc.$753
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$14,02889%
  • Education$1,77011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)52$1,143
Merck46$921
Novartis73$912
Johnson & Johnson32$905
Astellas Pharma US Inc23$839
Seagen Inc.19$753
Genentech USA, Inc.31$719
Daiichi Sankyo Inc.26$696
Amgen28$586
Pfizer48$568
Incyte Corporation14$512
EMD Serono, Inc.18$415
Bristol Myers Squibb18$388
E.r. Squibb & Sons, L.L.C.20$379
GSK19$353
Genmab U.S., Inc.15$321
Takeda Pharmaceuticals U.S.A., Inc.13$315
AbbVie14$297
Eisai Inc.14$291
Regeneron Healthcare Solutions, Inc.11$278
Lilly USA, LLC12$222
Sumitomo Pharma America, Inc.11$219
Gilead11$216
Sanofi10$215
Amneal Pharmaceuticals LLC9$189
Array Biopharma Inc10$159
Pharmacyclics LLC, An Abbvie Company8$148
Beone Medicines USA, Inc.7$144
Beigene USA, Inc.5$138
Tersera Therapeutics LLC6$132
Boehringer Ingelheim5$114
Jazz Pharmaceuticals Inc.4$111
Puma Biotechnology, Inc.6$110
Geron Corporation5$104
Deciphera Pharmaceuticals Inc.6$102
Sanofi-aventis U.S. LLC1$99
Rigel Pharmaceuticals, Inc.4$97
Karyopharm Therapeutics Inc.3$94
Pharmaessentia USA Corporation4$90
Helsinn Therapeutics (U.S.), Inc.5$86
Myriad Women's Health, Inc.1$84
Heron Therapeutics, Inc.4$79
Bayer4$75
Recordati_rare_diseases_inc.3$73
Servier Pharmaceuticals LLC3$71
Sobi, Inc3$68
Coherus Oncology, Inc.3$63
Genentech, Inc.1$53
Myovant Sciences Inc.3$52
Mylan Institutional Inc.2$51
Taiho Oncology, Inc.2$51
Ipsen Biopharmaceuticals, Inc3$49
Agios Pharmaceuticals, Inc.3$48
Springworks Therapeutics, Inc.2$43
Organon2$40
Pharmacosmos Therapeutics Inc.2$36
Tempus AI, Inc2$34
Morphosys, US Inc.2$33
X4 Pharmaceuticals, Inc.1$32
Mirati Therapeutics, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,798 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$912,874
Medicare patients
425
Services billed
52,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide13$263,905
BosulifBosutinib13$256,701
TagrissoOsimertinib Mesylate12$200,881
PromactaEltrombopag Olamine12$157,189
XareltoRivaroxaban24$19,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,595
Fentanyl23$2,246
Letrozole74$2,118
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$1,481
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$1,135
Tamoxifen Citrate32$732
Hydroxyurea26$709
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine18$574
Anastrozole25$574
Potassium Chloride19$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$388$263,90513 claims
PfizerBosulif$568$256,70113 claims
AstraZenecaTagrisso$1,143$200,88112 claims
NovartisPromacta$912$157,18912 claims
Johnson & JohnsonXarelto$905$19,77324 claims
GSKTrelegy Ellipta$353$6,59512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$189$15020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →